Clinical trial
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage…
NCT00458081 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00458081 |
|---|---|
| Title | Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors |
| Official title | A 12-month Multicentre, Randomised, Double-blind, Placebo-controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors. |
| Acronym | RIALTO |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia |
| Intervention type | Drug |
| Interventions | Rimonabant, Placebo |
| Enrollment | 174 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Apr 9, 2007 |
| Last update posted | Dec 10, 2010 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: